Lincoln Pharmaceuticals Limited

Lincoln Pharma holds 32nd AGM: Declares ₹1.80 dividend, reappoints directors

Lincoln Pharmaceuticals Limited's 32nd AGM on September 30, 2026, approved a dividend of ₹1.80 per share for FY25-26. Directors Hashmukh I. Patel and Munjal Mahendrabhai Patel were reappointed. The company adopted its FY25-26 financial statements and ratified auditor remuneration for FY26-27.

Lincoln Pharmaceuticals Appoints Pradeep Kumar Yadav as Senior General Manager - Quality Assurance

Lincoln Pharmaceuticals Limited appointed Mr. Pradeep Kumar Yadav as Senior General Manager - Quality Assurance, effective September 24, 2026. Mr. Yadav has over 20 years of experience in the pharmaceutical sector, with expertise in quality assurance and regulatory compliance.

Lincoln Pharmaceuticals: Sr. General Manager - QA (Head QA) Manoj Rai Resigns

Mr. Manoj Rai, Sr. General Manager - QA (Head QA) at Lincoln Pharmaceuticals Limited, has resigned due to personal reasons. His resignation is effective September 24, 2026. Mr. Rai is pursuing new professional opportunities and will ensure a smooth handover of responsibilities.

Lincoln Pharma: Trading Window Closed Oct 1, 2026, for Q3 FY27 Results

Lincoln Pharmaceuticals Limited will close its trading window from October 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ended September 30, 2026. Directors and key personnel are restricted from trading during this period.

Lincoln Pharma schedules 32nd AGM for Sept 30, announces dividend

Lincoln Pharmaceuticals Limited will hold its 32nd AGM on September 30, 2026, via VC/OAVM. The company recommended a dividend of ₹1.80 per share for FY26, subject to member approval. The Register of Members will close from Sept 12-30, 2026. Remote e-voting is available from Sept 26-29, 2026.

Lincoln Pharma Announces 32nd AGM on Sep 30, 2026, via VC/OAVM

Lincoln Pharmaceuticals Limited will hold its 32nd AGM on September 30, 2026, via VC/OAVM. Shareholders can access the Annual Report 2025-26 online. The company also reminds physical security holders to update KYC details as per SEBI mandate.

Lincoln Pharmaceuticals Ltd. announces 32nd AGM on Sep 30, 2026, proposes ₹1.80 dividend

Lincoln Pharmaceuticals Limited will hold its 32nd AGM on September 30, 2026, via VC/OAVM. The company proposes a dividend of ₹1.80 per share for FY26 and will consider re-appointing two directors. Financial statements for FY26 will also be adopted.

Lincoln Pharma Sets Record Date Sept 11 for 32nd AGM & 18% Final Dividend

Lincoln Pharmaceuticals Limited announced the record date as September 11, 2026, for its 32nd AGM and a final dividend. The AGM is on September 30, 2026. The company proposed an 18% final dividend (₹ 1.80 per share) for FY26.

Lincoln Pharmaceuticals Announces 32nd AGM on Sep 30, 2026

Lincoln Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026, at 11:00 a.m. IST. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means. Newspaper advertisements regarding the AGM have been published.

Lincoln Pharmaceuticals Ltd. Publishes Un-Audited Financial Results for Q1 FY27

Lincoln Pharmaceuticals Limited announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board on August 13, 2026, and published in newspapers. Full details are available on the company's website and stock exchange portals.

Lincoln Pharmaceuticals: Certificate for Quarter Ended June 30, 2026 Under SEBI Regs

Lincoln Pharmaceuticals Limited received a confirmation certificate from its RTA, MUFG Intime India Private Limited, for the quarter ended June 30, 2026. The certificate confirms the processing of dematerialisation requests as per SEBI regulations.

Lincoln Pharmaceuticals: Trading Window Closed July 1, 2026, for Q1 FY27 Results

Lincoln Pharmaceuticals Limited will close its trading window from July 1, 2026, for the quarter ending June 30, 2026. The window will reopen 48 hours after the declaration of unaudited financial results. Directors and key personnel are restricted from trading during this period.

Lincoln Pharmaceuticals Announces Audited Financial Results for FY Ended March 31, 2026

Lincoln Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. The results were approved by the Board on May 28, 2026, and published in newspapers on May 29, 2026.

Lincoln Pharmaceuticals Recommends 18% Dividend; Reports Q4 FY26 Results

Lincoln Pharmaceuticals recommended an 18% dividend (₹1.80 per share) for FY26. The Board approved audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. Unmodified audit opinions were received for the results.

Lincoln Pharmaceuticals declares 18% dividend; Q4 FY26 results announced

Lincoln Pharmaceuticals reported Q4 FY26 results with total income of ₹183.08 crore and net profit of ₹116.35 crore. For the full year FY26, total income was ₹704.48 crore and net profit was ₹878.94 crore. The company recommended an 18% dividend (₹1.80 per share) for FY26, pending AGM approval.

Lincoln Pharma Publishes Newspaper Ad for IEPF Share Transfer

Lincoln Pharmaceuticals Limited published a notice on May 08, 2026, about transferring unclaimed equity shares to the IEPF Authority. Shareholders with unclaimed dividends for seven consecutive years are urged to claim them, or their shares will be transferred.

Lincoln Pharma Clarifies Identical Standalone & Consolidated Q2 FY26 Results

Lincoln Pharmaceuticals Limited clarified identical standalone and consolidated financial results for the quarter ended September 30, 2025. This was due to its subsidiary having no financial transactions during the period. The clarification was provided to the NSE on January 8, 2026.

Lincoln Pharmaceuticals Files SEBI Certificate for Q4 FY26

Lincoln Pharmaceuticals Limited filed a certificate under SEBI regulations for the quarter ended March 31, 2026. The RTA confirmed processing of dematerialised securities. This is a routine compliance filing.

Lincoln Pharma: Trading Window Closed from April 1, 2026 for FY26 Audited Results

Lincoln Pharmaceuticals Limited will close its trading window from April 1, 2026, until 48 hours after the announcement of its audited financial results for the quarter and year ended March 31, 2026. This is in compliance with SEBI regulations.

Lincoln Pharma Q3 FY26 Earnings Call Transcript Released

Lincoln Pharmaceuticals reported Q3 FY26 revenue of ₹166.32 Cr, up from ₹146.55 Cr YoY. EBITDA increased to ₹38.74 Cr and Net Profit to ₹28.60 Cr. The company targets ₹1,000 Cr revenue, driven by domestic growth, regulatory market entries, and a new R&D center. International expansion in Canada, Australia, and EU is progressing.

Lincoln Pharma Releases Audio Recording of Q3 FY26 Earnings Call

Lincoln Pharmaceuticals Limited has released the audio recording of its conference call for the quarter and nine months ended December 31, 2025. The recording is available on the company's website.

Lincoln Pharma Schedules Earnings Conference Call for Q3 & 9M FY26 Results on Feb 18

Lincoln Pharmaceuticals Limited will hold an earnings conference call on February 18, 2026, at 4:00 p.m. IST to discuss financial results for the quarter and nine months ended December 31, 2025. The call will feature Whole Time Director Mr. Munjal Patel.

Lincoln Pharmaceuticals Ltd. Announces Un-audited Financial Results for Q3 FY26

Lincoln Pharmaceuticals Limited announced its un-audited financial results for Q3 FY26. The Board of Directors approved the standalone and consolidated results on February 12, 2026. Full details are available on the company and stock exchange websites.

Lincoln Pharma Q3 FY26 Net Profit Surges 37.7% to ₹28.60 Cr; Revenue up 13.49%

Lincoln Pharmaceuticals reported a Q3 FY26 consolidated net profit of ₹28.60 crore, up 37.70% YoY. Revenue rose 13.49% to ₹166.32 crore. For 9MFY26, net profit was ₹76.26 crore (up 7.76%) and revenue was ₹483.75 crore (up 6.31%). The company targets ₹1,000 crore revenue in 3 years with 15-18% annual growth.

Lincoln Pharmaceuticals' Credit Ratings Reaffirmed: CRISIL A/Stable and CRISIL A1

Lincoln Pharmaceuticals Limited's long-term bank facilities are reaffirmed at CRISIL A/Stable and short-term facilities at CRISIL A1 by CRISIL on January 9, 2026. The ratings are supported by promoter experience, market position, and financial health. Revenue grew 14% to ₹623 crore in FY25.

Lincoln Pharma submits SEBI compliance certificate for Q3 FY26

Lincoln Pharmaceuticals Limited submitted a compliance certificate for the quarter ended December 31, 2025. The certificate was issued by the RTA, MUFG Intime India Private Limited, confirming the processing of dematerialised securities.

Lincoln Pharmaceuticals Closes Trading Window From Jan 1, 2026, For Q4 Results

Lincoln Pharmaceuticals will close its trading window from January 1, 2026, until 48 hours after the declaration of Q4 FY26 financial results. This is in compliance with SEBI regulations regarding insider trading.

Lincoln Pharmaceuticals Publishes Un-Audited Q2 & H1 FY26 Financial Results in Newspapers

Lincoln Pharmaceuticals published un-audited standalone and consolidated financial results for Q2 and H1 ended September 30, 2025, in Financial Express, approved by the Board on November 13, 2025.

Lincoln Pharma reports Q2 FY26 net profit of ₹20.01 crore, approves ₹1.80 dividend for FY24-25

Lincoln Pharma reported Q2 FY26 consolidated net profit of ₹20.01 crore, a 24.06% Y-o-Y decrease. Total income was ₹170.60 crore, down 0.34%. The company approved a ₹1.80 dividend for FY24-25 and targets ₹1,000 crore revenue in three years.

Lincoln Pharma's 31st AGM Approves Financials, ₹1.80 Dividend, and Key Director Re-appointments

Lincoln Pharma's 31st AGM on September 30, 2025, approved FY25 financial statements, declared a ₹1.80 dividend, and re-appointed key directors including Mr. Mahendra G. Patel as MD, ensuring stable leadership and shareholder returns.

Special window for re-lodgment of transfer requests for physical shares

Lincoln Pharma announces a special window for re-lodgment of physical share transfer requests, following SEBI guidelines. Contact details for RSTA Link Intime India Pvt. Ltd are provided for queries.

Submission of Certificate under SEBI Regulations for Quarter Ended 30 Sep 2025

Lincoln Pharmaceuticals submits compliance certificate under SEBI regulations for the quarter ended September 30, 2025, confirming dematerialization of securities.

Lincoln Pharma announces 31st AGM voting results; all resolutions passed including ₹1.80 dividend and director re-appointments

Lincoln Pharmaceuticals announced that all resolutions, including a ₹1.80 dividend and director re-appointments, were passed at its 31st AGM on September 30, 2025.

Lincoln Pharma informs shareholders about AGM, Annual Report & KYC update

Lincoln Pharma to hold 31st AGM on 30 September 2025, proposes ₹1.80 dividend

Lincoln Pharmaceuticals appoints Raja Karunanidhi Nagarajan as Senior General Manager - R&D

Lincoln Pharma announces record date and book closure for AGM and final dividend

Appointment of Secretarial Auditor

Lincoln Pharmaceuticals re-appoints Directors

Lincoln Pharma Q1 FY26 Net Profit up 16.93% Y-o-Y to ₹27.70 Crore; Targets ₹1,000 Crore Revenue in 3 Years